Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Gross Profit (2016 - 2025)

Historic Gross Profit for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $15.6 million.

  • Anika Therapeutics' Gross Profit fell 1970.32% to $15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.8 million, marking a year-over-year decrease of 447.21%. This contributed to the annual value of $76.0 million for FY2024, which is 791.69% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Gross Profit is $15.6 million, which was down 1970.32% from $14.4 million recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Gross Profit peaked at $29.0 million during Q2 2023, and registered a low of $3.8 million during Q4 2022.
  • Moreover, its 5-year median value for Gross Profit was $20.5 million (2024), whereas its average is $18.9 million.
  • Its Gross Profit has fluctuated over the past 5 years, first crashed by 7918.28% in 2022, then skyrocketed by 19665.69% in 2024.
  • Anika Therapeutics' Gross Profit (Quarter) stood at $18.1 million in 2021, then crashed by 79.18% to $3.8 million in 2022, then skyrocketed by 52.93% to $5.8 million in 2023, then skyrocketed by 196.66% to $17.1 million in 2024, then decreased by 9.0% to $15.6 million in 2025.
  • Its last three reported values are $15.6 million in Q3 2025, $14.4 million for Q2 2025, and $14.7 million during Q1 2025.